NBTX vs. AEON, FHTX, XERS, PRLD, TSVT, TELO, PYXS, XBIT, NKTR, and PBYI
Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include AEON Biopharma (AEON), Foghorn Therapeutics (FHTX), Xeris Biopharma (XERS), Prelude Therapeutics (PRLD), 2seventy bio (TSVT), Telomir Pharmaceuticals (TELO), Pyxis Oncology (PYXS), XBiotech (XBIT), Nektar Therapeutics (NKTR), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry.
Nanobiotix (NASDAQ:NBTX) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.
Nanobiotix received 7 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 60.00% of users gave Nanobiotix an outperform vote.
38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 20.0% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Nanobiotix has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
AEON Biopharma has lower revenue, but higher earnings than Nanobiotix.
In the previous week, AEON Biopharma had 11 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for AEON Biopharma and 1 mentions for Nanobiotix. AEON Biopharma's average media sentiment score of 0.87 beat Nanobiotix's score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the news media.
Nanobiotix presently has a consensus price target of $11.00, suggesting a potential upside of 86.44%. AEON Biopharma has a consensus price target of $18.00, suggesting a potential upside of 348.88%. Given AEON Biopharma's higher probable upside, analysts plainly believe AEON Biopharma is more favorable than Nanobiotix.
Summary
AEON Biopharma beats Nanobiotix on 7 of the 12 factors compared between the two stocks.
Get Nanobiotix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nanobiotix Competitors List
Related Companies and Tools
